# Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

> **NCT01427257** · PHASE1 · COMPLETED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 10 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Single Dose PB1023
- **DRUG:** Single Dose PB1023
- **DRUG:** Single Dose PB1023

## Key facts

- **NCT ID:** NCT01427257
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01427257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01427257, "Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01427257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*